Is Sonoma Pharmaceuticals going out of business?

SONOMA PHARMACEUTICALS, INC. (SNOA) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

SONOMA PHARMACEUTICALS, INC. (SNOA) scores 28 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 134.37% (YoY)

Five questions, kept separate

Survival - Funding dependent

13-18 mo of estimated runway from 2026-06-30, based on $5.3M of cash and short-term investments against $4.1M of annual burn. Adjusted shares outstanding increased 134.4% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

24.6% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: 134.37% (YoY)
• ROIC: -117.35%
• Revenue CAGR (3Y): 13.74%
• Debt / Equity: No financial debt (debt-free)
• Revenue growth YoY: 59.55% (YoY) - Growth from a low base; sustainability uncertain.
• Return on Assets: -17.53%
• Revenue Quality: High-quality (DSO -4d, Rev +60%)
• FCF margin: -21.12% (Inv. Mode)
• Cash Burn Deceleration: -3.13% QoQ improvement (Worsening)
• Working Capital Efficiency: 5410.50x (Well-funded)
• Asset Growth Velocity: 24.07% YoY
• Debt Maturity Runway: 0% long-term (Near-term refinancing risk)

Read from filings through 2026-08-06.

Price as of 2026-09-07.